{"artifact":{"id":"rsc-h-5e0c4ddf-f77fe5f8","artifact_type":"rigor_score_card","entity_ids":null,"title":"Rigor Score Card: IL-33/ST2 Axis Augmentation for Synaptic Protection","quality_score":0.3,"created_by":"rigor_score_card","provenance_chain":"[{\"artifact_id\": \"h-5e0c4ddf\", \"relation\": \"scores\"}]","content_hash":null,"metadata":{"dimensions":["scientific_premise","study_design","blinding","power_analysis","resource_identification","statistical_reporting","data_availability","sabv"],"eval_a_raw":{"scores":{"sabv":{"score":1,"evidence":"In APP/PS1 transgenic mice (Alzheimer's model): Daily IL-33 intraperitoneal injection (0.5 μg/kg) for 4 weeks reduces cortical amyloid plaque burden by 35%","location":"Preclinical Evidence section"},"blinding":{"score":1,"evidence":"Daily IL-33 intraperitoneal injection (0.5 μg/kg) for 4 weeks reduces cortical amyloid plaque burden by 35%, decreases soluble Aβ40/42 by 45%, and improves spatial memory in Morris water maze to wild-type performance levels.","location":"Preclinical Evidence section"},"study_design":{"score":2,"evidence":"Phase I/II trials for Alzheimer's disease could use: Patient selection: Early AD (MCI due to AD or mild AD dementia); biomarker-confirmed amyloid positivity","location":"Clinical Development Path section"},"power_analysis":{"score":1,"evidence":"Daily IL-33 intraperitoneal injection (0.5 μg/kg) for 4 weeks reduces cortical amyloid plaque burden by 35%","location":"Preclinical Evidence section"},"data_availability":{"score":1,"evidence":"IL-33/ST2 axis augmentation for synaptic protection proposes that increasing interleukin-33 (IL-33) signaling through its receptor ST2 (IL1RL1) can restore synaptic function","location":"Title/Opening paragraph"},"scientific_premise":{"score":3,"evidence":"Serum IL-33 levels are significantly decreased in Alzheimer's disease patients (by 40-50% vs. age-matched controls), and this decrease correlates inversely with amyloid PET SUVr and cognitive impairment severity.","location":"IL-33 in Alzheimer's Disease: Clinical Evidence section"},"statistical_reporting":{"score":1,"evidence":"Daily IL-33 intraperitoneal injection (0.5 μg/kg) for 4 weeks reduces cortical amyloid plaque burden by 35%, decreases soluble Aβ40/42 by 45%, and improves spatial memory in Morris water maze to wild-type performance levels.","location":"Preclinical Evidence section"},"resource_identification":{"score":2,"evidence":"In APP/PS1 transgenic mice (Alzheimer's model): Daily IL-33 intraperitoneal injection (0.5 μg/kg) for 4 weeks reduces cortical amyloid plaque burden by 35%","location":"Preclinical Evidence section"}},"overall_summary":"This hypothesis text presents a scientifically plausible mechanism for IL-33/ST2 axis augmentation but demonstrates severe deficiencies in methodological rigor across most dimensions. It lacks any mention of blinding, power analysis, statistical methods, or sex disaggregation. The clinical development plan is aspirational rather than designed with rigor. Preclinical efficacy claims are presented without supporting evidence quality documentation.","weakest_dimension":"Data Availability - no mention of data/code sharing, combined with multiple major deficiencies in blinding, power analysis, statistical reporting, and SABV","strongest_dimension":"Scientific Premise - the text provides mechanistic rationale, clinical biomarker correlations, and genetic validation, though specific prior publications are not cited"},"eval_b_raw":{"scores":{"sabv":{"score":1,"evidence":"No mention of sex-based analyses, sex as a biological variable, or disaggregation by sex","location":"Entire document"},"blinding":{"score":1,"evidence":"No mention of blinding procedures or assessor blinding in any described study","location":"Entire document"},"study_design":{"score":2,"evidence":"Daily IL-33 intraperitoneal injection (0.5 μg/kg) for 4 weeks reduces cortical amyloid plaque burden by 35%, decreases soluble Aβ40/42 by 45%","location":"Preclinical Evidence section"},"power_analysis":{"score":1,"evidence":"No mention of sample size calculation, statistical power justification, or power analysis","location":"Entire document"},"data_availability":{"score":1,"evidence":"No data repositories, code availability statements, or access provisions mentioned","location":"Entire document"},"scientific_premise":{"score":3,"evidence":"The critical discovery that positioned IL-33 as a therapeutic target for Alzheimer's disease is its role in driving microglia toward an anti-inflammatory, tissue-repair phenotype","location":"IL-33 as a Microglial Polarization Switch section"},"statistical_reporting":{"score":1,"evidence":"No statistical tests, p-values, confidence intervals, or correction methods reported","location":"Entire document"},"resource_identification":{"score":2,"evidence":"APP/PS1 transgenic mice (Alzheimer's model) and 5×FAD mice (aggressive amyloid model)","location":"Preclinical Evidence section"}},"overall_summary":"This hypothesis text presents a plausible scientific rationale for IL-33/ST2 axis augmentation in Alzheimer's disease with extensive mechanistic detail, but exhibits severe methodological deficiencies across multiple rigor dimensions. Critical gaps include absence of statistical reporting (no p-values, confidence intervals, or test specifications), no blinding procedures, no power analysis, and no consideration of sex as a biological variable. The document describes preclinical outcomes with quantitative results but provides no statistical methodology or transparency.","weakest_dimension":"statistical_reporting","strongest_dimension":"scientific_premise"},"provider_a":"minimax","provider_b":"glm","reconciled":{"reconciler_notes":"Both evaluators demonstrated exceptional concordance across all 8 rigor dimensions, assigning identical scores in every category. For dimensions where scores differed slightly (none in this case), the rule would be to average when difference ≤1. Since no differences exist, all scores are taken as-is. Notable patterns: (1) Scientific premise is the strongest dimension (3/3) with evaluators citing complementary clinical biomarker evidence (A) and mechanistic rationale (B); (2) Five dimensions (blinding, power_analysis, statistical_reporting, data_availability, sabv) are uniformly deficient (1/3), reflecting severe methodological gaps in the text; (3) Both evaluators independently identified the absence of statistical transparency as a critical weakness. The perfect Cohen's kappa of 1.0 indicates complete inter-rater reliability, suggesting robust and consistent evaluation criteria were applied.","overall_agreement":"high","reconciled_scores":{"sabv":{"score":1,"a_score":1,"b_score":1,"a_evidence":"In APP/PS1 transgenic mice (Alzheimer's model): Daily IL-33 intraperitoneal injection (0.5 μg/kg) for 4 weeks reduces cortical amyloid plaque burden by 35%","b_evidence":"No mention of sex-based analyses, sex as a biological variable, or disaggregation by sex","disagreement":false},"blinding":{"score":1,"a_score":1,"b_score":1,"a_evidence":"Daily IL-33 intraperitoneal injection (0.5 μg/kg) for 4 weeks reduces cortical amyloid plaque burden by 35%, decreases soluble Aβ40/42 by 45%, and improves spatial memory in Morris water maze to wild-type performance levels.","b_evidence":"No mention of blinding procedures or assessor blinding in any described study","disagreement":false},"study_design":{"score":2,"a_score":2,"b_score":2,"a_evidence":"Phase I/II trials for Alzheimer's disease could use: Patient selection: Early AD (MCI due to AD or mild AD dementia); biomarker-confirmed amyloid positivity","b_evidence":"Daily IL-33 intraperitoneal injection (0.5 μg/kg) for 4 weeks reduces cortical amyloid plaque burden by 35%, decreases soluble Aβ40/42 by 45%","disagreement":false},"power_analysis":{"score":1,"a_score":1,"b_score":1,"a_evidence":"Daily IL-33 intraperitoneal injection (0.5 μg/kg) for 4 weeks reduces cortical amyloid plaque burden by 35%","b_evidence":"No mention of sample size calculation, statistical power justification, or power analysis","disagreement":false},"data_availability":{"score":1,"a_score":1,"b_score":1,"a_evidence":"IL-33/ST2 axis augmentation for synaptic protection proposes that increasing interleukin-33 (IL-33) signaling through its receptor ST2 (IL1RL1) can restore synaptic function","b_evidence":"No data repositories, code availability statements, or access provisions mentioned","disagreement":false},"scientific_premise":{"score":3,"a_score":3,"b_score":3,"a_evidence":"Serum IL-33 levels are significantly decreased in Alzheimer's disease patients (by 40-50% vs. age-matched controls), and this decrease correlates inversely with amyloid PET SUVr and cognitive impairment severity.","b_evidence":"The critical discovery that positioned IL-33 as a therapeutic target for Alzheimer's disease is its role in driving microglia toward an anti-inflammatory, tissue-repair phenotype","disagreement":false},"statistical_reporting":{"score":1,"a_score":1,"b_score":1,"a_evidence":"Daily IL-33 intraperitoneal injection (0.5 μg/kg) for 4 weeks reduces cortical amyloid plaque burden by 35%, decreases soluble Aβ40/42 by 45%, and improves spatial memory in Morris water maze to wild-type performance levels.","b_evidence":"No statistical tests, p-values, confidence intervals, or correction methods reported","disagreement":false},"resource_identification":{"score":2,"a_score":2,"b_score":2,"a_evidence":"In APP/PS1 transgenic mice (Alzheimer's model): Daily IL-33 intraperitoneal injection (0.5 μg/kg) for 4 weeks reduces cortical amyloid plaque burden by 35%","b_evidence":"APP/PS1 transgenic mice (Alzheimer's model) and 5×FAD mice (aggressive amyloid model)","disagreement":false}},"inter_rater_agreement":"1.0 (perfect agreement)","dimensions_with_disagreement":[]},"_schema_version":1,"scored_entity_id":"h-5e0c4ddf","scored_entity_type":"hypothesis","scored_entity_title":"IL-33/ST2 Axis Augmentation for Synaptic Protection"},"created_at":"2026-04-24T04:42:02.632152-07:00","updated_at":"2026-04-24T04:42:02.632155-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"internal","origin_url":null,"lifecycle_changed_at":"2026-04-24T04:42:02.632152-07:00","citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":null,"contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"169b1d31-6e42-4f4b-a941-a47ebd22c1f5","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"rigor_score_card"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[],"incoming_links":[],"current_artifact_id":"rsc-h-5e0c4ddf-f77fe5f8","is_canonical":true,"supersede_chain":["rsc-h-5e0c4ddf-f77fe5f8"]}